Scott M. Coiante is CFO & SVP at Aprea Therapeutics, Inc. (APRE). They have made 1 open-market trade across 1 company since 2019, most recently 2026-02-28.
CIK 0001608536
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $38K since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APRE | BUY | 2019-10-07 | 2019-10-07 | $15.00 | $38K | +1.4% | +23.8% | +111.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.